Mid-Year Report

AMGEN, INC. for AMGEN INC

Firm
Client
Income
—
Expenses
$9,080,000

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Contacted: Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Corporate Tax Issues

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); SENATE; Office of Management & Budget (OMB); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Copyright/Patent/Trademark CPT

Intellectual property and process patent issues S. 1145 and S. 1908 – Patent Reform Act of 2007

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB)

Bills named: S. 1908 (110th), S. 1145 (110th)

Health Issues HCR

Follow-On-Biologics S. 623 and H.R. 1038 – Access to Life-Saving Medicines Act H.R. 1956 – Patient Protection and Innovative Biologic Medicines Act of 2007 S. 1695 - Biologics Price Competition and Innovation Act of 2007 FDA Drug Safety Oversight S.1082 – Prescription Drug User Fee Amendments of 2007 H.R. 2900 – Food and Drug Administration Amendments Act of 2007

Contacted: U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2900 (110th), H.R. 1956 (110th), S. 1695 (110th), H.R. 1038 (110th), S. 623 (110th), S. 1082 (110th)

Medicare/Medicaid MMM

Implementation of H.R. 1 Medicare Prescription Drug & Modernization Act of 2003 Medicare coverage and reimbursement of Erythropoiesis-Stimulating Agents Implementation of Medicaid Drug Rebate provisions of the Deficit Reduction Act of 2005

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.